AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.
about
Mitochondrial Stat3, the Need for Design ThinkingImage-based detection and targeting of therapy resistance in pancreatic adenocarcinoma.Stat3 regulates desmoglein 3 transcription in epithelial keratinocytes.The notorious R.N.A. in the spotlight - drug or target for the treatment of diseaseAlteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy.The curious origins of angioimmunoblastic T-cell lymphomaLong Noncoding RNAs in Cancer PathwaysResponse of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibininThe Novel miR-9600 Suppresses Tumor Progression and Promotes Paclitaxel Sensitivity in Non-small-cell Lung Cancer Through Altering STAT3 Expression.Targeted depletion of PIK3R2 induces regression of lung squamous cell carcinomaLuteolin selectively kills STAT3 highly activated gastric cancer cells through enhancing the binding of STAT3 to SHP-1.New Modalities for Challenging Targets in Drug Discovery.Do STAT3 inhibitors have potential in the future for cancer therapy?Generation of an inducible mouse model to reversibly silence Stat3.Inhibition of STAT3 with the Generation 2.5 Antisense Oligonucleotide, AZD9150, Decreases Neuroblastoma Tumorigenicity and Increases Chemosensitivity.An oxidative stress-based mechanism of doxorubicin cytotoxicity suggests new therapeutic strategies in ABC-DLBCL.The Non-Coding Transcriptome of Prostate Cancer: Implications for Clinical Practice.Stem and progenitor cell alterations in myelodysplastic syndromes.Autologous reconstitution of human cancer and immune system in vivo.Targeting Long Noncoding RNA with Antisense Oligonucleotide Technology as Cancer Therapeutics.JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer.Role of STAT3 in Genesis and Progression of Human Malignant Gliomas.Targeting cancer-related inflammation in the era of immunotherapy.Molecular Subtyping in Diffuse Large B Cell Lymphoma: Closer to an Approach of Precision Therapy.STAT3 inhibition for cancer therapy: Cell-autonomous effects only?E-cadherin downregulation sensitizes PTEN-mutant tumors to PI3Kβ silencing.CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell-Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1.A sensible approach to targeting STAT3-mediated transcription.Androgen receptor in cancer-associated fibroblasts influences stemness in cancer cells.Benzyl Isothiocyanate (BITC) Induces Reactive Oxygen Species-dependent Repression of STAT3 Protein by Down-regulation of Specificity Proteins in Pancreatic Cancer.Antisense Oligonucleotides Targeting Y-Box Binding Protein-1 Inhibit Tumor Angiogenesis by Downregulating Bcl-xL-VEGFR2/-Tie Axes.Long Noncoding RNA in Cancer: Wiring Signaling Circuitry.EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma.RNA Therapeutics in Oncology: Advances, Challenges, and Future Directions.Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs.Therapeutic Applications of Targeted Alternative Splicing to Cancer Treatment.Therapeutic Targeting of Long Non-Coding RNAs in Cancer.B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors.Targeting the IL-6/JAK/STAT3 signalling axis in cancer.Hypermethylation of antisense long noncoding RNAs in acute lymphoblastic leukemia.
P2860
Q26750616-E56C895F-410D-4071-AF65-D748DC39AA03Q30803684-23B3E055-205D-4E76-A646-8AA5EB9AFA06Q33631072-38BF423D-FD56-4C9D-8759-19703FE0D791Q33739733-1657B335-48E7-4F20-A5C8-EABC0CAC682BQ33838824-B8A37DB4-D619-4860-BFE4-182B0DF9A5D2Q33877993-944965BD-7827-46A6-ACD2-7C0DFC939EC5Q36796798-7A25824F-C7C5-4E76-92CB-345AEB96B1EDQ37362587-6722E0EB-FA18-4C0E-AF7A-CF7C698CCE99Q37501595-9D16FEE7-97EE-4A1C-B3D4-EA9C75D492B4Q37709086-C39AC0A1-9D78-4717-B23C-441BD19301CAQ37745238-D16F628C-B65C-4D1A-9A88-11102FEE4065Q38289100-00F2A8ED-93EB-4964-82D1-BB4CDCAEF894Q38656557-D28CCDBA-5BE9-49B8-8C78-94CC525CA077Q38717511-CE8D049A-C8CA-4A1E-A02B-CBF84F60640FQ38734933-50733DBB-0294-4C65-AE62-F63E17CBDE6FQ38741291-4F051B3B-3B64-41B8-9715-5EC259F96691Q38744451-28C341DF-8B06-4E04-A900-C282FAC40EAEQ38761791-70E8F4A8-7F30-47D4-B53C-FD462099A830Q38779010-FDE2CCC6-D0AC-4B09-82DA-BB164A298C30Q38807425-89BB3841-DA98-4E36-A2E5-995118A6EECEQ38839108-D602552D-9A2D-47D7-8BF4-665C84CFF5ABQ38962315-5B57E8D6-BACE-4D38-9CF2-A4883D1184FEQ39044981-CE58681F-EDD0-4238-80E1-F9F2A3B602C5Q39147488-5BD45A99-6DB4-4DB6-A621-9A90D48EFD60Q39550361-12A702BD-9F4E-4B4E-A209-EEC2904563EFQ42118139-B0BADF91-E283-4587-92F9-351CE804916DQ42289005-6E4E952D-B056-4D5A-9FF2-548513404E06Q42370338-BB6F589E-DA35-4845-9A09-032042601626Q46140457-E4DCDDC6-094A-480B-BD6E-EC43CAC60975Q46456077-67683D17-7618-4955-88F1-B817469387A1Q47156365-BDC31E0A-E201-454C-86F3-492C7B92C1D5Q47258279-DB572D2C-D7D3-403A-B7B5-9657F99D058FQ47780922-F5058066-8DD5-4E73-97A8-E69B558596F4Q47786398-F3772428-A8A7-4FC5-B463-1525775F8805Q48569299-605C7EBD-FA67-45C4-B23B-D47FD361B792Q49519966-BA7137BC-6149-45B8-A23B-F70176FAA638Q49961986-188FF68A-AFC0-4D81-A545-5BF511F593A6Q50056654-51D5658C-D07E-4718-9D77-6EFFFF982F7FQ50191433-3CC45969-43DE-4049-BDB9-ACCFF7311A05Q50461322-EDA6A9A2-229D-42B9-BCEA-47F621107D09
P2860
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
AZD9150, a next-generation ant ...... y in lymphoma and lung cancer.
@en
AZD9150, a next-generation ant ...... y in lymphoma and lung cancer.
@nl
type
label
AZD9150, a next-generation ant ...... y in lymphoma and lung cancer.
@en
AZD9150, a next-generation ant ...... y in lymphoma and lung cancer.
@nl
prefLabel
AZD9150, a next-generation ant ...... y in lymphoma and lung cancer.
@en
AZD9150, a next-generation ant ...... y in lymphoma and lung cancer.
@nl
P2093
P2860
P1476
AZD9150, a next-generation ant ...... y in lymphoma and lung cancer.
@en
P2093
A Robert MacLeod
Alexey Revenko
Anas Younes
Brett P Monia
Corinne Reimer
David C Blakey
David Hong
Deborah Lawson
Joanna Schmidt
P2860
P304
P356
10.1126/SCITRANSLMED.AAC5272
P407
P577
2015-11-01T00:00:00Z